Japanese immunology, biochemistry and healthtech pioneer, Cellspect is developing breakthrough highly portable point-of-care-testing (POCT) devices that can address the needs of dispersed populations.

Their innovative POCT solutions are ushering in a new era of simple, fast, and accurate blood testing which can be easily done by the patient themselves, at home, work, or elsewhere.  Cellspect has also miniaturized conventional POCT into a smart-device driven platform that enables detection using mobile apps, that can detect multiple bio-parameters, simultaneously, from very limited samples, such as a single drop of blood.  These innovative tools are enabling anyone to easily self-monitor, addressing the challenge of empowering anyone, anywhere to access their state of health freely.

Current, biochemical tests include sugar metabolism, lipid and COVID-19 antigen, and more tests for cardiovascular diseases and infectious diseases, will be released in the near future, bringing true self-testing to a new digital age.

Visit: Cellspect

Products include ready-to-use kits for measuring biomarkers, for use in academic, medical and epidemiological research, and education; government approved clinical in-vitro diagnostic drug test kits for use in medical testing institutions, government agencies, sample measurement rooms, etc., and a clinical test contract service.

In 2019, Jameel Health began a collaboration with Cellspect to bring these low-cost POCT devices to developing markets across the global south.